- Home
- TARS vs INDV Comparison
TARS vs INDV Comparison
Compare TARS & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARS | INDV |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.2B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TARS | INDV |
|---|---|---|
| Price | $68.26 | $34.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $99.80 | $49.00 |
| AVG Volume (30 Days) | 652.8K | ★ 1.7M |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 48.21 | ★ 8100.00 |
| EPS | N/A | ★ 1.67 |
| Revenue | $451,360,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | $61.17 | $7.50 |
| Revenue Next Year | $26.47 | $5.07 |
| P/E Ratio | ★ N/A | $21.04 |
| Revenue Growth | ★ 146.71 | 4.29 |
| 52 Week Low | $53.89 | $24.28 |
| 52 Week High | $91.53 | $42.81 |
Technical Indicators
Market Signals| Indicator | TARS | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 45.45 |
| Support Level | $60.95 | $32.39 |
| Resistance Level | $74.51 | $35.70 |
| Average True Range (ATR) | 3.34 | 1.29 |
| MACD | -0.37 | -0.01 |
| Stochastic Oscillator | 2.22 | 53.84 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).